Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a drug calm brain inflammation after stroke? new trial aims to find out

NCT ID NCT07263776

Disease control Sponsor: Capital Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 18, 2026 · Updated 2 times

Summary

This study tests whether adding an interleukin-6 receptor inhibitor (a drug that reduces inflammation) to standard emergency stroke treatment helps people recover better after a severe stroke caused by a large blood clot in the front part of the brain. About 692 adults who are eligible for emergency clot removal will receive either the drug or a placebo. The main goal is to see if the drug improves disability levels three months after the stroke.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 692 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 18 years or greater, male or female; 2. Acute ischemic stroke caused by occlusion of intracranial segment of the internal carotid artery, middle cerebral artery M1 or proximal/dominant M2 segment; 3. Decided to undergo emergency endovascular treatment; 4. Time from stroke onset to arterial puncture within 24 hours; 5. National Institutes of Health Stroke Scale (NIHSS) score ≥ 6; 6. Signed informed consent from the patients or the legally authorized representatives. Exclusion Criteria: 1. Intracerebral hemorrhage, epidural hematoma, subdural hematoma, intraventricular hemorrhage, or subarachnoid hemorrhage; 2. Pre-stroke modified Rankin scale (mRS) score \>1; 3. Known allergy to tocilizumab or excipients; 4. Known allergy to iodinated contrast agents; 5. Anticipated difficulty in completing endovascular treatment due to vascular tortuosity; 6. History of congenital or acquired bleeding disorders, coagulation factor deficiency diseases, or thrombocytopenic diseases; 7. Systolic blood pressure ≥180mmHg or diastolic blood pressure ≥110mmHg despite blood pressure control; 8. Neutrophils \<2×109 /L; 9. Platelets \<100×109 /L; 10. Blood glucose \<2.8mmol/L (50 mg/dL) or \>22.2mmol/L (400 mg/dL); 11. Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels \>2 times the upper limit of normal; 12. Known recent or current serum creatinine \>2 times the upper limit of normal or estimated glomerular filtration rate (eGFR) \<60 mL/min; 13. Pregnant, lactating, or planning pregnancy within 90 days; 14. Severe mental disorders or inability to comply with informed consent and follow-up requirements due to dementia; 15. Concurrent malignant tumors or severe systemic diseases with expected survival of less than 90 days; 16. Presence of autoimmune diseases or use of immunosuppressive drugs; 17. Systemic infectious diseases; 18. Participation in another interventional clinical study within 30 days before randomization or currently participating in another interventional clinical study; 19. Considered by the investigator to have other conditions that might affect compliance or preclude participation in this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute anterior circulation large vessel occlusion stroke are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ischemic stroke large artery stroke stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute ischemic stroke

Contacts and locations

Locations

  • Beijing Red Cross Emergency Medical Center

    Beijing, China

  • Binzhou Medical University Hospital

    Binzhou, Shandong, China

  • Daliuta Experimental District People's Hospital of Shenmu City

    Yulin, Shanxi, China

  • Henan Provincial People's Hospital

    Zhengzhou, Henan, China

  • Huixian People's Hospital

    Xinxiang, Henan, China

  • Jiaozuo No.2 People's Hospital

    Jiaozuo, Henan, China

  • Jiaxing First Hospital

    Jiaxing, Zhejiang, China

  • Jincheng People's Hospital

    Jincheng, Shanxi, China

  • JingDong ZhongMei Hospital

    Langfang, Hebei, China

  • Jun County People's Hospital

    Hebi, Henan, China

  • Lingshan County People's Hospital

    Qinzhou, Guangxi, China

  • Linshu Country People's Hospital

    Linyi, Shandong, China

  • Linyi People's Hospital

    Linyi, Shandong, China

  • Lishui Central Hospital

    Lishui, Zhejiang, China

  • Luoyang Central Hospital

    Luoyang, Henan, China

  • Mengjin County People's Hospital

    Luoyang, Henan, China

  • Nantong First People's Hospital

    Nantong, Jiangsu, China

  • Nanyang Central Hospital

    Nanyang, Henan, China

  • Nanyang Nanshi Hospital

    Nanyang, Henan, China

  • Nanyang Second People's Hospital

    Nanyang, Henan, China

  • Ningbo Medical Center Lihuili Hospital

    Ningbo, Zhejiang, China

  • Ningbo NO.2 Hospital

    Ningbo, Zhejiang, China

  • Ningling County People's Hospital

    Shangqiu, Henan, China

  • People's Hospital of Dongying

    Dongying, Shandong, China

  • Puyang Oilfield General Hospital

    Puyang, Henan, China

  • Qingdao Huangdao District Hospital of Traditional Chinese Medicine

    Qingdao, Shandong, China

  • Shangqiu No.1 People's Hospital

    Shangqiu, Henan, China

  • Shanxi Bethune Hospital

    Taiyuan, Shanxi, China

  • Shanxi Medical University First Hospital

    Taiyuan, Shanxi, China

  • Shenzhen Longhua District People's Hospital

    Shenzhen, China

  • Si Country People's Hospital

    Suzhou, Anhui, China

  • Suixi County Hospital

    Suzhou, Anhui, China

  • Suzhou Hospital of Anhui Medical University

    Suzhou, Anhui, China

  • Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University

    Taizhou, Zhejiang, China

  • Tanghe County People's Hospital

    Nanyang, Henan, China

  • Tangshan Workers Hospital

    Tangshan, Hebei, China

  • The First Affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang, China

  • The First Affiliated Hospital of Henan Medical University

    Xinxiang, Henan, China

  • The People's Hospital of Anyang

    Anyang, Henan, China

  • The People's Hospital of Xianyang

    Xianyang, Shanxi, China

  • The second Hospital of Qinhuangdao

    Qinhuangdao, Hebei, China

  • Tianyou Hospital Affliated to Wuhan University of Science &Technology

    Wuhan, Hubei, China

  • Wenzhou People's Hospital

    Wenzhou, Zhejiang, China

  • Xiangyang No.1 People's hospital

    Xiangyang, Hubei, China

  • Xihua County People's Hospital

    Zhoukou, Henan, China

  • Xing'an league People's Hospital

    Xing’an, Inner Mongolia, China

  • Xinxiang Central Hospital

    Xinxiang, Henan, China

  • Xuanwu Hospital, Capital Medical University

    Beijing, 100053, China

  • Yiyuan Country People's Hospital

    Zibo, Shandong, China

  • Yueqing People's Hospital

    Yueqing, Zhejiang, China

  • Yutian Hospital

    Tangshan, Hebei, China

  • Zhangzhou Municipal Hospital

    Zhangzhou, Fujian, China

  • Zhongxiang Traditional Chinese Medical Hospital

    Zhongxiang, Wuhan, China

  • Zibo Central Hospital

    Zibo, Shandong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.